Abstracts tagged "Infection"

Abstract Number: 1594 • ACR Convergence 2022
Incidence of Pneumocystis Jirovecii Pneumonia and Prophylaxis-Associated Adverse Events Among Patients with Systemic Lupus Erythematosus
Yiran Jiang¹, Ali Duarte-Garcia², Mike Putman³ and David Gazeley⁴, ¹Medical College of Wisconsin, Milwaukee, WI, ²Mayo Clinic, Rochester, MN, ³The Medical College of Wisconsin, Milwaukee, WI, ⁴Medical College of Wisconsin, Wauwatosa, WI
Background/Purpose: Pneumocystis jirovecii Pneumonia (PJP) is an opportunistic infection that may affect patients receiving immunosuppression. There are no consensus guidelines for PJP prophylaxis among patients…
Abstract Number: 2275 • ACR Convergence 2022
Three Dose SARS-CoV-2 Vaccination Is Associated with Reduced Risk of Breakthrough COVID-19 During Omicron Wave in Patients with Autoimmune Diseases
Caoilfhionn Connolly¹, Rachel Wallwork¹, Teresa Po-Yu Chiang¹, Mayan Teles¹, Jennifer Alejo¹, Allan Massie², Ami Shah³, Jemima Albayda¹, Lisa Christopher-Stine¹, Dorry Segev², William Werbel¹ and Julie Paik¹, ¹Johns Hopkins University, Baltimore, MD, ²NYU Langone Health, New York, NY, ³Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: While SARS-CoV-2 vaccination mitigates the risk of severe COVID-19, vaccinated patients with autoimmune diseases are more susceptible to infection despite vaccination ("breakthrough" COVID-19) and…
Abstract Number: 0720 • ACR Convergence 2022
Risk-Benefit Assessment of Primary Prophylaxis for Pneumocystis Pneumonia in Patents with Rheumatic Diseases Exposed to Rituximab: A Multicenter Cohort Study
Jun Won Park¹, Jeffrey Curtis², Min Jung Kim³, You-Jung Ha⁴, Yun Jong Lee⁴ and Eun Bong Lee¹, ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, Republic of Korea, ⁴Seoul National University Bundang Hospital, Seongnam, Republic of Korea
Background/Purpose: Although previous studies suggested that primary prophylaxis for pneumocystis pneumonia (PJP) during rituximab treatment could be beneficial, it is uncertain whether this strategy should…
Abstract Number: 1071 • ACR Convergence 2022
Trimethoprim Sulfamethoxazole Use in Patients with Granulomatosis with Polyangiitis Treated with Rituximab
Arielle Mendel¹, Hassan Behlouli², Cristiano Moura², Evelyne Vinet¹, Jeffrey Curtis³ and Sasha Bernatsky², ¹McGill University Health Centre, Montréal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ³Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Trimethoprim sulfamethoxazole (TMP-SMX) prophylaxis is recommended during induction of ANCA-associated vasculitis (AAV) to prevent pneumocystis jirovecii pneumonia (PJP), and may also reduce the risk…
Abstract Number: 1704 • ACR Convergence 2022
Interaction of Macrophages and Natural Killer Cells in Pathogenesis of HIV-1-Associated Inflammatory Arthritis
Can Sungur¹, Gao Hongbo¹, Li-ping Yang², Liang Shan¹ and Wayne Yokoyama³, ¹Washington University, St. Louis, MO, ²Washington University in St. Louis, St. Louis, MO, ³Washington University School of Medicine, St. Louis, MO
Background/Purpose: Human immunodeficiency virus (HIV) remains a significant life-threatening agent and burden on public health. Lesser studied and understood aspects of HIV infections include HIV-associated…
Abstract Number: 0747 • ACR Convergence 2022
Methotrexate and Hydroxychloroquine Used as Single Agent May Diminish Breakthrough Infection After COVID-19 Vaccination
Haihui Wang¹ and Andras Perl², ¹Upstate Medical University, Fayetteville, NY, ²SUNY, Syracuse, NY
Background/Purpose: Immunosuppressive medications generally predispose patients to greater risk of serious complications upon COVID-19 infection. This study was initiated to assess whether individual drugs may…
Abstract Number: 1274 • ACR Convergence 2022
Improving Pneumococcal Vaccination Rates Among Immunosuppressed Adults in an Academic Rheumatology Clinic Utilizing a Nurse Driven Protocol
Elena Joerns¹, Nagendra Pokala², Dan Wang³, Joan Reisch³, Reuben Arasaratnam³, Bonnie Bermas¹ and Puneet Bajaj³, ¹UT Southwestern, Dallas, TX, ²University of Texas Southwestern Medical Center, Dallas, TX, ³UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Rheumatology patients are at risk for severe pneumococcal infections due to their underlying disease and immunosuppressive therapy. Current Advisory Committee on Immunization Practices guidelines…
Abstract Number: 1705 • ACR Convergence 2022
Peptidoglycan Amplifies CD4+ T Cell Activation by MHCII+ Fibroblast-like Synoviocytes in an in Vitro Model of Lyme Arthritis
Joseph Rouse¹, Amanda Wahhab¹, Rebecca Danner¹, Brandon Jutras², Adam Edelstein³, Klemen Strle⁴ and Robert Lochhead⁵, ¹Medical College of Wisconsin, Milwaukee, WI, ²Virginia Tech, Blacksburg, VA, ³Northwestern Medicine, Chicago, IL, ⁴Wadsworth Center, Albany, NY, ⁵Medical College of Wisconsin, Germantown, WI
Background/Purpose: Lyme arthritis (LA), caused by infection with Borrelia burgdorferi (Bb), is characterized by proliferative synovitis accompanied by dysregulated autoimmune Th1 responses. Fibroblast-like synoviocytes (FLS)…
Abstract Number: 0750 • ACR Convergence 2022
Quality Improvement Project to Increase the Rate of Vaccination with Pneumococcal Vaccines (PCV13 prime-PPSV23 Boost Strategy) Among Adult Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) Within Nationwide Health Organization
Victoria Furer, Hagit Sarbagil-Maman and Ori Elkayam, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Background/Purpose: Patients with autoimmune inflammatory rheumatic diseases (AIIRD) are susceptible for pneumococcal disease. Two vaccines against S. pneumoniae are currently recommended for use: a 23-valent…
Abstract Number: 1282 • ACR Convergence 2022
Practice Patterns for Pneumocystis Jiroveci Pneumonia (PJP) Prophylaxis Among Nephrologists and Rheumatologists – an International Survey Study
Swati Arora¹, Brad Rovin² and Tanmayee Bichile³, ¹Allegheny Health Network, Pittsburgh, ²The Ohio State University, Columbus, OH, ³Allegheny Health Network, Gibsonia, PA
Background/Purpose: Patients with autoimmune disorders such as systemic lupus erythematosus (SLE), lupus nephritis (LN) and granulomatosis with polyangiitis (GPA) frequently require treatment with immunosuppressive drugs.…
Abstract Number: 1728 • ACR Convergence 2022
Increased Frequency of Highly Differentiated T Effector Memory Cells Re-expressing CD45RA (Temra) and Cytomegalovirus Seropositivity Are Associated with Persistent Disease Specifically Refractory to Anti-TNF Therapy in Rheumatoid Arthritis
Su-Ann Yeoh, James Kimpton, Muhammad Shipa, Eleanor Hawkins, Arne Akbar and Michael Ehrenstein, University College London, London, United Kingdom
Background/Purpose: Enrichment of highly differentiated T cells have been reported in rheumatoid arthritis (RA) patients compared to healthy individuals. The role of highly differentiated T…
Abstract Number: L16 • ACR Convergence 2021
Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled Electronic Medical Record Data Repository
Jasvinder Singh¹, Namrata Singh², Alfred Anzalone³, Amy Olex⁴, Jing Sun⁵, Vithal Madhira⁶ and Rena Patel⁷, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Washington, Bellevue, WA, ³University of Nebraska, Omaha, NE, ⁴Virginia Commonwealth University, Richmond, VA, ⁵Johns Hopkins University, Baltimore, MD, ⁶Palila Software, Reno, NV, ⁷Unviersity of Washington, Seattle, WA
Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether breakthrough COVID-19 infections were increased post-COVID-19-vaccination…
Abstract Number: 0444 • ACR Convergence 2021
COVID-19 Vaccination in Autoimmune Disease (CoVAD) Study: Interim Analysis of Safety in Idiopathic Inflammatory Myopathies from a Large Multicentre Global Survey
Latika Gupta¹, James Lilleker², Vishwesh Agarwal³, Sinan Kardes⁴, Marcin Milchert⁵, Tamer Gheita⁶, Babur Salim⁷, Tsvetelina Velikova⁸, Oliver Distler⁹, Hector Chinoy¹⁰, Vikas Aggarwal¹ and Rohit Aggarwal¹¹, ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, ²Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, The University of Manchester, Centre for Musculoskeletal Research,, Manchester, United Kingdom, ³Mahatma Gandhi Mission Medical College, Navi Mumbai, India, ⁴Medical Ecology and Hydroclimatology Istanbul Faculty of Medicine, Istanbul, Turkey, ⁵Katedra Reumatologii i Chorób Wewnętrznych, Klinika Chorób Wewnętrznych Reumatologii Diabetologii Geriatrii i Immunologii Klinicznej PUM, ul. Unii Lubelskiej 1, 71-252 Szczecin,, Szczecin, Poland, ⁶Cairo University, Egypt, Cairo, Egypt, ⁷Fauji Foundation Hospital, Rawalpindi, Pakistan, ⁸University Hospital Lozenetz, Sofia, Bulgaria, ⁹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland, ¹⁰University of Manchester, Salford, United Kingdom, ¹¹University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Numerous Covid-19 vaccines have demonstrated efficacy and safety against SARS-CoV-2 in general population. Despite favorable adverse effect (ADRs) profile of vaccines, there have been…
Abstract Number: 1359 • ACR Convergence 2021
Risk of Respiratory Tract Infections with Biologic and Targeted Synthetic Antirheumatic Agents in Psoriatic Arthritis: A Systematic Review and Network Meta-analysis
Yi-Shao Liu¹, Jawad Bilal², Muhammad Ajmal², Syed Arsalan Ahmed Naqvi³, Zaina Shahid⁴, Kaneez Zahra Rubab Khakwani², Farva Gondal⁵, Irbaz Bin Riaz⁶, Sandipan Bhattacharjee¹, Roxanne Bogucka¹ and C. Kent Kwoh⁷, ¹University of Texas at Austin, Austin, TX, ²University of Arizona, Tucson, AZ, ³Dow University of Health Sciences, Karachi, Pakistan, ⁴Lehigh Valley Health Network, Allentown, PA, ⁵University of Arizona College of Medicine, Tucson, AZ, ⁶Mayo Clinic, Phoenix, AZ, ⁷University of Arizona College of Medicine, Tuscon, AZ
Background/Purpose: A variety of biologic and targeted synthetic disease modifying antirheumatic agents have been widely used among patients with psoriatic arthritis (PsA). Due to the…
Abstract Number: 1783 • ACR Convergence 2021
National Trends in Hospitalizations for Serious Infections in People with Psoriatic Arthritis Using the National Inpatient Sample 2012 – 2017
Vagishwari Murugesan¹, Eleni Pilitsi², Gabriela Rabasa³ and Maureen Dubreuil⁴, ¹Boston University Medical Center, Boston, MA, ²Boston Medical Center, Boston, MA, ³Boston University, Boston, MA, ⁴Boston University School of Medicine/ VA Boston, Boston, MA
Background/Purpose: Given that uptake of biologic therapies has increased over recent years, we sought to investigate the national trends in serious infections in patients with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].